Onset of multiple sclerosis associated with anti-TNF therapy
Abstract
Therapies aimed at inhibiting tumor necrosis factor (TNF), a proinflammatory cytokine implicated in autoimmune disease are effective, especially for rheumatoid arthritis. We report a patient with new onset MS closely associated with the initiation of anti-TNF therapy for juvenile rheumatoid arthritis. It is possible that the inhibition of TNF triggered MS in this individual.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Hohlfeld R. Inhibitors of tumor necrosis factor-alpha: promising agents for the treatment of multiple sclerosis? Mult Scler . 1996; 1: 376–378.
2.
Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature . 1995; 377: 348–351.
3.
Segal BM, Cross AH. Fas(t) track to apoptosis in MS: TNF receptors may suppress or potentiate CNS demyelination. Neurology . 2000; 55: 906–907.
4.
Raza A. Anti-TNF therapies in rheumatoid arthritis, Crohn’s disease, sepsis, and myelodysplastic syndromes. Microsc Res Tech . 2000; 50: 229–235.
5.
Powell MB, Mitchell D, Lederman J, et al. Lymphotoxin and tumor necrosis factor-alpha production by myelin basic protein-specific T cell clones correlates with encephalitogenicity. Int Immunol . 1990; 2: 539–544.
6.
Selmaj KW, Raine CS. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor anti-bodies and soluble tumor necrosis factor receptors. Neurology . 1995; 45 (6 suppl 6): S44–S49.
7.
Selmaj K, Raine CS, Cannella B, Brosnan CF. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest . 1991; 87: 949–954.
8.
The Lerencept Multiple Sclerosis Study Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology . 1999; 53: 457–465.
9.
van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology . 1996; 47: 1531–1534.
10.
Fernandez-Botran R. Soluble cytokine receptors: novel immunotherapeutic agents. Expert Opin Invest Drugs . 2000; 9: 497–514.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: June 20, 2001
Accepted: August 8, 2001
Published online: November 27, 2001
Published in print: November 27, 2001
Authors
Metrics & Citations
Metrics
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Neurological Side Effects of TNF-α Inhibitors Revisited: A Review of Case Reports, Medicina, 60, 9, (1409), (2024).https://doi.org/10.3390/medicina60091409
- Management of Uveitis Patients on Anti-TNF Agents Who Develop Demyelinating Disease – A Case Series, Journal of Ophthalmic Inflammation and Infection, 14, 1, (2024).https://doi.org/10.1186/s12348-024-00403-3
- Evaluation of Optical Coherence Tomography Angiography Findings in Pars Planitis and Multiple Sclerosis Associated Intermediate Uveitis in Remission, Current Eye Research, 49, 7, (717-724), (2024).https://doi.org/10.1080/02713683.2024.2323520
- TNFR2 signalling in inflammatory diseases, Best Practice & Research Clinical Rheumatology, 38, 2, (101941), (2024).https://doi.org/10.1016/j.berh.2024.101941
- Ido2 Deficiency Exacerbates Motor Impairment and Reduces Aryl Hydrocarbon Receptor Activity through Decreased Kynurenine in a Chronic Demyelinating Mouse Model, Molecular Neurobiology, (2024).https://doi.org/10.1007/s12035-024-04263-9
- Risk of Neuroinflammatory Diseases Among New Recipients of Biologic and Targeted Synthetic Disease‐Modifying Antirheumatic Drugs, Arthritis Care & Research, 76, 8, (1203-1209), (2024).https://doi.org/10.1002/acr.25340
- Secondary Central Nervous System Demyelinating Disorders in the Elderly: A Narrative Review, Healthcare, 11, 15, (2126), (2023).https://doi.org/10.3390/healthcare11152126
- Therapeutic potential of TNFR2 agonists: a mechanistic perspective, Frontiers in Immunology, 14, (2023).https://doi.org/10.3389/fimmu.2023.1209188
- Inflammation-inducible promoters to overexpress immune inhibitory factors by MSCs, Stem Cell Research & Therapy, 14, 1, (2023).https://doi.org/10.1186/s13287-023-03501-6
- Anti-IL-5 biologics and rheumatoid arthritis: a single-centre 500 patient year exposure analysis, RMD Open, 9, 4, (e003583), (2023).https://doi.org/10.1136/rmdopen-2023-003583
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.